Primary Progressive Multiple Sclerosis
If approved, the monoclonal antibody will be the first treatment indicated for both RMS and PPMS.
The new drug shows promise in the treatment of PPMS, for which there are currently no approved treatments.
Combined results confirmed that intrathecal LCN2 production was increased in MS patients, especially those with SPMS and PPMS.
Natalizumab treatment linked to 15.9% increase of value in JC virus.
The results suggest that addressing depression may help improve other symptoms, like pain and fatigue.
MS clinical trials have triple the success rate of those focused on other diseases.
There is currently no approved treatments for RMS that have been shown to change the course of the disease.
Neurology Advisor Articles
- Comorbidities in Multiple Sclerosis: Effects on DMTs, the Treatment Team, and More
- New Diagnostic Criteria for Neurosarcoidosis: What You Need to Know
- FDA Approves Powerful New Opioid Despite Criticisms
- Guidelines on the Use of OnabotulinumtoxinA for Chronic Migraine
- Efficacy of Naftazone on Motor Symptoms of Parkinson Disease
- Guideline for Diagnosis and Treatment of Idiopathic Intracranial Hypertension
- Ivy League Rule Change Linked to Fewer Concussions During NCAA Football Games
- Addressing Levodopa-Resistant Parkinson Disease
- Pediatric Migraine: Evidence-Based Alternative Management
- High-Dose Biotin May Be an Effective Treatment for Progressive MS
- Circadian, Circaseptan Rhythms Prevalent in Epileptic Seizure Cycles
- Jolt Accentuation of Headache Not a Universal Indicator of Acute Meningitis
- Reduced Survival for Patients With Idiopathic Parkinsonism
- ACA Implementation Decreased Rates of Therapy Nonadherence in Stroke Survivors
- Fluorescence Can ID High-Grade Glioma During Sx for Brain Tumor